MUNDIPHARMA
11.9.2020 10:38:24 CEST | Business Wire | Press release
Mundipharma is delighted to announce that Great Place to Work® - the global authority on workplace culture – has named it as one of Europe’s Best Workplaces™.
Mundipharma is ranked 12th out of 25 organisations in the Multi-National Company category. Great Place to Work® have recognised a total of 125 organisations across four categories in its newly published Europe’s Best Workplaces™ 2020 list.
Great Place to Work analyzed survey results representing 3,000 organisations and 1.5 million employees across Europe. The survey measured trust and engagement of employees using a series of statements designed to evaluate experience of organizational culture.
This European achievement was made possible after Great Place to Work® presented a number of National ‘Best Workplaces™ awards to Mundipharma companies earlier this year, including Spain, Netherlands, Portugal and Napp.
These European awards follow similar success from across the global Mundipharma network including across the Asia Region. So far this year, Hong Kong, China, Myanmar and Vietnam have all received ‘Best Company’ recognitions from prestigious national awarding bodies.
Speaking about the results, Mundipharma’s Global CEO, Marc Princen, said “Awards like these are testament to our focus on building an inclusive learning culture at Mundipharma where every employee feels appreciated. We believe that people are our most valued asset and if individuals feel accountable, and have the power to make a difference, they can not only deliver for the business but more importantly for the patients we serve.”
The EU list publication has come during the COVID-19 pandemic, which has placed unprecedented pressures upon businesses and employees globally. Organizations on the list are being celebrated for leading the way amid the pandemic, demonstrating care for their employees, their customers and their communities during difficult and exceptional times.
-Ends-
Notes to editors:
About Great Place to Work
Great Place to Work® identifies the top organizations that create great workplaces in the European region through publishing the annual Best Workplaces in Europe list. List determinations are based on thorough analysis of confidential employee feedback through the Trust Index™ survey and a Culture Audit™ examining company practices. The list recognizes companies in four size categories: Small (20-49 employees); Medium (50-499 employees); Large (500+ employees); and Multinational.
To be considered for inclusion, companies must appear on one or more national lists in the region, which includes Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Norway, Poland, Portugal, Spain, Sweden, Switzerland, Turkey, The Netherlands, and the United Kingdom.
Multinational organizations must meet the following requirements: 1) Have at least 1,000 employees worldwide, with at least 40% (or 5,000) of those employees based outside the headquarters country; and 2) Appear on at least three national best workplaces lists. Multinationals also receive additional credit for their efforts to successfully create an excellent workplace culture in multiple countries in the region. The data used in the calculation of the regional list comes from national lists published in late 2019 and early 2020.
About the Mundipharma network
Mundipharma is a global (ex-US) network of privately-owned independent associated companies with a presence across Africa, Asia Pacific, Europe, Canada, Latin America and the Middle East.
We are dedicated to bringing to patients with severe and debilitating diseases the benefit of novel treatment options in fields such as Anti-Infectives, Biosimilars, CNS, Diabetes, Oncology & supportive care, Ophthalmology, Pain Management, Respiratory and Consumer Healthcare.
For further information by geographic region please go to www.mundipharma.com (Europe); www.purdue.ca (Canada) and www.mundipharma.com.sg (other ex-US markets).
View source version on businesswire.com: https://www.businesswire.com/news/home/20200911005140/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
REPLY: The Board of Directors Approved the Draft Financial Statements for the Year 202512.3.2026 15:38:00 CET | Press release
All economic indicators are positive.Consolidated turnover of €2,483.6 million (€2,300.5 million in 2024);EBITDA at €467.6 million (€410.6 million in 2024);EBIT at €391.7 million (€330.4 million in 2024)Group net profit at €250.9 million (€211.1 million in 2024)Approval of the proposed dividend distribution of €1.35 per share. Today the Board of Directors of Reply S.p.A. [MTA, STAR: REY] approved the draft financial statement for the year 2025, which will be submitted for approval to the Shareholders’ Meeting to be held in first call in Turin on 23 April 2026. The Reply Group closed 2025 with a consolidated turnover of €2,483.6 million, an increase of 8.0% compared to €2,300.5 million in 2024. All indicators are positive for the period. Consolidated EBITDA was €467.6 million, an increase of 13.9% compared to €410.6 million at December 2024. EBIT, from January to December, was at €391.7 million, which is an increase of 18.5% compared to €330.4 million at December 2024. The Group net pro
LZE GmbH Introduces Fraunhofer’s RFicient® Technology to the Market12.3.2026 14:51:00 CET | Press release
LZE GmbH is expanding its technology transfer portfolio and making the RFicient® ultra-low-power wake-up receiver technology from the Fraunhofer Institute for Integrated Circuits IIS available for the first time as a standard chip for close-to-production industrial applications. The solution enables energy-efficient IoT designs that remain continuously reachable while consuming only microamps – a key step for long-lasting, low-maintenance IoT products. LZE GmbH drives technology transfer to market: standard chip availability for close-to-production applications As a bridge between research and industry, LZE GmbH is making it easier for companies to access innovative technologies and helping them to quickly and reliably transform new developments into market-ready solutions. With RFicient®-IC (FH101RF), LZE is providing another high-tech product that comes directly from Fraunhofer research and can now be ordered in volume and integrated into close-to-production product development for t
Owkin Creates New Spin out Waiv, Formerly Owkin Dx, With $33M Financing12.3.2026 14:30:00 CET | Press release
Investment lead by OTB Ventures and Alpha Intelligence CapitalWaiv develops AI-powered precision testing to better identify and stratify patients in the clinic and in clinical trials, transforming patient careWaiv extends Owkin’s strategy of real-world validation for its AI Owkin, the AI company on a mission to solve the complexity of biology, today announced the spin out of Waiv, formerly known as Owkin Dx. The move follows significant investor interest and positions Waiv to bring AI-powered precision testing for better identification of patients in the clinic and in clinical trials, to transform patient care. This follows on from the successful launch of Bioptimus, an Owkin incubated company, in February 2024. Waiv translates AI innovation into real-world clinical impact, developing tests that predict biomarkers and patient outcomes, including RlapsRisk BC for prognostic risk profiling. With multiple tests already in use in clinical settings, its deployment platform Destra, and colla
RQM+ Launches SMART Solutions Life Cycle Partnership Model12.3.2026 14:30:00 CET | Press release
Helps MedTech Companies Navigate MDR, IVDR, and AI-Enabled Device Development RQM+, a leading MedTech CRO offering regulatory consulting, clinical trial, laboratory, and reimbursement services, today announced the launch of SMART Solutions, a life cycle partnership model designed to help medical device and diagnostics companies manage growing regulatory and development complexity. SMART Solutions introduces a strategy-led operating framework that unifies regulatory, quality, clinical, reimbursement, and laboratory expertise to support MedTech companies across the entire product life cycle to help reduce risk from early development through post-market. “MedTech companies are navigating unprecedented complexity as regulatory expectations evolve, product innovation accelerates, and post-market expectations are expanding,” said John Potthoff, Ph.D., chief executive officer of RQM+. “SMART Solutions moves beyond traditional consulting by providing an integrated life cycle partnership that h
Cryptio Raises $45m Series B as Digital Assets Move Into Regulated Financial Markets12.3.2026 14:06:00 CET | Press release
The system of record for tokenized finance – ERP infrastructure for institutions operating in digital assets Cryptio, a leader in financial data transformation and enterprise resource planning (ERP) applications for regulated digital assets, announced today a $45 million Series B funding round co-led by BlackFin Capital Partners and Sentinel Global, with participation from 1kx, Alven, BlueYard Capital and Ledger Cathay Capital. Banks, exchanges, asset managers, including Société Générale’s SG Forge, Circle, Gemini, and Securitize rely on Cryptio to ensure financial integrity across their digital assets businesses. Existing ERP systems fall short for digital assets Traditional ERP and accounting systems were not designed for blockchain-native assets, real-time reporting, or modern custody frameworks. As regulated financial institutions expand into stablecoins, tokenized securities and other on-chain instruments, these limitations create material operational and reporting challenges. Cry
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
